IL165593A0 - Use of an alpha2delta ligand such as gabapentin orpregabalin for treating attention deficit hyperac tivity disorder - Google Patents
Use of an alpha2delta ligand such as gabapentin orpregabalin for treating attention deficit hyperac tivity disorderInfo
- Publication number
- IL165593A0 IL165593A0 IL16559303A IL16559303A IL165593A0 IL 165593 A0 IL165593 A0 IL 165593A0 IL 16559303 A IL16559303 A IL 16559303A IL 16559303 A IL16559303 A IL 16559303A IL 165593 A0 IL165593 A0 IL 165593A0
- Authority
- IL
- Israel
- Prior art keywords
- orpregabalin
- hyperac
- tivity
- gabapentin
- ligand
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title 1
- 229960002870 gabapentin Drugs 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39214002P | 2002-06-27 | 2002-06-27 | |
| PCT/IB2003/002666 WO2004002462A2 (en) | 2002-06-27 | 2003-06-16 | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL165593A0 true IL165593A0 (en) | 2006-01-15 |
Family
ID=30000817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16559303A IL165593A0 (en) | 2002-06-27 | 2003-06-16 | Use of an alpha2delta ligand such as gabapentin orpregabalin for treating attention deficit hyperac tivity disorder |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040006073A1 (de) |
| EP (1) | EP1515709A2 (de) |
| JP (1) | JP2005534678A (de) |
| CN (1) | CN1678298A (de) |
| AU (1) | AU2003239752A1 (de) |
| BR (1) | BR0312240A (de) |
| CA (1) | CA2488566A1 (de) |
| IL (1) | IL165593A0 (de) |
| MX (1) | MXPA04012922A (de) |
| PL (1) | PL375090A1 (de) |
| TW (1) | TW200400025A (de) |
| WO (1) | WO2004002462A2 (de) |
| ZA (1) | ZA200409848B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| AU2004233863B2 (en) * | 2003-04-24 | 2010-06-17 | Incyte Holdings Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| US7910108B2 (en) | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| AU2008213908B2 (en) * | 2007-02-07 | 2013-07-25 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
| WO2008095221A1 (en) * | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| AU2009279372A1 (en) | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
| MY196791A (en) | 2016-05-06 | 2023-05-03 | Esteve Pharmaceuticals Sa | New tetrahydropyrimidodiazepin and dihydropyridodiazepin compounds for treating pain and pain related conditions |
| KR102956231B1 (ko) | 2023-10-12 | 2026-04-23 | 재단법인대구경북과학기술원 | 포스폰산 디페닐아민 화합물 및 이를 포함하는 페로브스카이트 태양전지 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) * | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| NZ334898A (en) * | 1996-10-23 | 2000-09-29 | Warner Lambert Co | Substituted gamma aminobutyric acids as pharamceutical agents |
| WO1999031075A1 (en) * | 1997-12-16 | 1999-06-24 | Warner-Lambert Company | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
| ES2216338T3 (es) * | 1997-12-16 | 2004-10-16 | Warner-Lambert Company Llc | Aminas novedosas como agentes farmaceuticos. |
| KR20010033153A (ko) * | 1997-12-16 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 4(3)-치환-4(3)-아미노메틸-(티오)피란 또는 -피페리딘유도체(=가바펜틴 동족체), 그의 제법 및 신경 질환 치료용도 |
| EP1082306A1 (de) * | 1998-05-26 | 2001-03-14 | Warner-Lambert Company | Aminosäureverbindungen mit starrer konformation mit affinität für die alpha2delta untereinheit eines calciumkanals |
| HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
| US6462084B1 (en) * | 2001-05-14 | 2002-10-08 | Brookhaven Science Associates, Llc | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
-
2003
- 2003-06-16 EP EP03732941A patent/EP1515709A2/de not_active Withdrawn
- 2003-06-16 WO PCT/IB2003/002666 patent/WO2004002462A2/en not_active Ceased
- 2003-06-16 CN CNA038202131A patent/CN1678298A/zh active Pending
- 2003-06-16 PL PL03375090A patent/PL375090A1/xx not_active Application Discontinuation
- 2003-06-16 IL IL16559303A patent/IL165593A0/xx unknown
- 2003-06-16 AU AU2003239752A patent/AU2003239752A1/en not_active Abandoned
- 2003-06-16 CA CA002488566A patent/CA2488566A1/en not_active Abandoned
- 2003-06-16 JP JP2004517096A patent/JP2005534678A/ja not_active Withdrawn
- 2003-06-16 BR BR0312240-9A patent/BR0312240A/pt not_active IP Right Cessation
- 2003-06-16 MX MXPA04012922A patent/MXPA04012922A/es unknown
- 2003-06-23 US US10/602,414 patent/US20040006073A1/en not_active Abandoned
- 2003-06-26 TW TW092117444A patent/TW200400025A/zh unknown
-
2004
- 2004-12-06 ZA ZA200409848A patent/ZA200409848B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL375090A1 (en) | 2005-11-14 |
| CN1678298A (zh) | 2005-10-05 |
| CA2488566A1 (en) | 2004-01-08 |
| AU2003239752A1 (en) | 2004-01-19 |
| EP1515709A2 (de) | 2005-03-23 |
| BR0312240A (pt) | 2005-04-12 |
| ZA200409848B (en) | 2005-06-23 |
| TW200400025A (en) | 2004-01-01 |
| US20040006073A1 (en) | 2004-01-08 |
| WO2004002462A3 (en) | 2004-03-11 |
| WO2004002462A2 (en) | 2004-01-08 |
| JP2005534678A (ja) | 2005-11-17 |
| MXPA04012922A (es) | 2005-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217623A (en) | Amino-carbonyl-boron compound is converted | |
| PT2308507E (pt) | Métodos de tratamento de pré-eclâmpsia | |
| DE602005009748D1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
| IL169633A0 (en) | Combination therapy for treating protein deficiencies | |
| EP1677794A4 (de) | Verfahren zur behandlung einer erkrankung | |
| AU2003259494A8 (en) | Current source for cryptographic processor | |
| EP1505961A4 (de) | Verfahren zur behandlung allergischer reaktionen | |
| CY2013031I2 (el) | Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους | |
| DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| MXPA03008634A (es) | Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades. | |
| DE602004022153D1 (de) | Verbindungen zur behandlung von obesitas | |
| AU2003293998A1 (en) | Use of alkyl resorcinols in the treatment of acne | |
| EP1694364A4 (de) | System zur behandlung und prävention von brustkrebs | |
| AU2003280010A1 (en) | Methods for treating attention deficit disorder | |
| PL371944A1 (en) | Alpha 2 delta ligands to treat tinnitus | |
| ZA200301390B (en) | Method of enhancing skin lightening. | |
| AU2003222065A8 (en) | Chemiluminescent treatment of acne | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| LT1496918T (lt) | Natrio meta-arsenito naudojimas navikams gydyti | |
| PL375090A1 (en) | Method of treating attention deficit hyperactivity disorder | |
| MXPA06000700A (es) | Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6. | |
| MXPA04000272A (es) | Derivados de 4-aminociclohexanol sustituidos. | |
| MX2008001638A (es) | Metodo de espaciado de piel entumecida. | |
| PL1682488T3 (pl) | Sposób otrzymywania gabapentyny | |
| MY140194A (en) | Novel fusidic acid derivatives |